A similar conversation is now emerging around obesity medicines: GLP-1 and dual agonists are being recognised internationally as evidence-based treatments for obesity with cardiometabolic benefit.[8] Indian insurers may progressively consider coverage when obesity is severe and linked with diabetes, heart disease, or sleep apnoea, rather than for cosmetic weight loss alone.[10] For families, this could mean negotiating group policies and reading the policy wording carefully to see if medically supervised GLP-1 therapy for obesity-with-complications is covered
A study coming out in the next month or so is expected to show a 20% reduction in heart attacks, strokes, and death from a cardiovascular cause
Many people find that their biology, metabolism, and hormonal balance create roadblocks that require more than just willpower
The challenge with elbow tendon injuries lies in the poor blood supply tendons receive
Sermorelin is a truncated 29-amino-acid chain that mimics natural GHRH but degrades very rapidly in living tissues
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the company) includes forward-looking statements within the meaning of the safe harbor provisions of the U.S
